On behalf of Medix Pharmaceuticals Americas, Inc., the U.S. distributor of Biafine, I am writing to express deep concern over the following review article that appeared in <i>Oncology Nursing Forum</i> (Vol. 31, pp. 237-247): "Prevention and Treatment of Acute Radiation Dermatitis: A Literature Review" by Mihkaila Maurine Wickline. The article misrepresents the current state of the scientific literature and does a disservice to oncology healthcare professionals and patients alike. Although my following comments focus primarily on the author's comments and conclusions regarding Biafine, I have no reason to believe that her comments regarding other radiation therapies are valid.